Vistagen Therapeutics, Inc. (VTGN)
VTGNNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.1854
+0.0216 (+13.19%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $8.18m
- P/E
- –
- EPS, last 4 quarters
- $-1.66
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1638 to $5.14
- Average volume
- 12.72m
- Previous close
- $0.1638
Earnings
next estimate $-0.3700Next report Nov 12, 2026
Sep 2025
-5.9%
Dec 2025
+11.8%
Mar 2026
+11.9%
Jun 2026
-3.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $258.0k | $302.0k | $465.0k | $1.48m |
| Gross profit | $258.0k | $302.0k | $465.0k | $1.48m |
| Operating income | -$20.05m | -$19.55m | -$16.72m | -$13.35m |
| Net income | -$19.42m | -$18.90m | -$16.27m | -$13.03m |
Last four quarters: revenue $2.50m, margin -2703.7%, free cash flow –
News
8 latest- Vistagen Therapeutics, Inc. Announces Regulatory Update Following Type C Meeting with FDA on Phase 3 Development of FasedienolFintel · 11 hours ago
- Vistagen To Revise Phase 3 Fasedienol Trial Plan After FDA Feedback RTTNews · 16 hours ago
- SRX Global Liquidates 2 Portfolio Investments, Adds Onconetix Ahead Of Realbotix Deal RTTNews · Sep 25, 2026
- Vistagen Reports Positive Findings Supporting Fasedienol's Potential In Very Severe SAD RTTNews · Sep 24, 2026
- Vistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock Up RTTNews · Sep 22, 2026
- Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path RTTNews · Aug 14, 2026
- SRX Global Acquires Stake In Vistagen Therapeutics; Shares Edge Higher In Pre-Market RTTNews · Aug 4, 2026
- Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal RTTNews · Jul 2, 2026
The company
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen's pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen's most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- vistagen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.